Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials.

ABSTRACT:

Background

PREDICT v2.2 is a prognostic tool used to estimate 5- and 10-year overall survival (OS) rates in early-stage breast cancer (BC). While it has been validated in several populations, limited data exist on its performance in cohorts derived from randomized clinical trials.

Materials and methods

This study analyzed individual data from patients with early-stage BC enrolled in five phase III randomized clinical trials conducted by the Gruppo Italiano Mammella (GIM) and Mammella InterGruppo (MIG) between 1992 and 2012. Patients with stage IV disease, prior neoadjuvant therapy, or missing data were excluded. PREDICT v2.2 was used to calculate 5- and 10-year OS predictions. Observed survival was derived using Kaplan-Meier estimates, and the model's calibration and discrim

SUBMITTER: Borea R 

PROVIDER: S-EPMC12808956 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature